Series of negative events and environment was dragging down the stock.
Key resistance of 9.2 was not broken in August, taking it into downtrend.
Yet, the fundamentally the company is undervalued and flies under radar.
It will start grasping more attention as COVISTIX and G-MAB library products will continue progressing with approvals.
In short term TA indicates the reversal with breaking-up the long downtrend.
Based on my own analysis and research I foresee price target of 20-22, which is ~3x from current level.
Short interest of ca. 17% will most likely be a fuel once the catalyst events materialize.
Key resistance of 9.2 was not broken in August, taking it into downtrend.
Yet, the fundamentally the company is undervalued and flies under radar.
It will start grasping more attention as COVISTIX and G-MAB library products will continue progressing with approvals.
In short term TA indicates the reversal with breaking-up the long downtrend.
Based on my own analysis and research I foresee price target of 20-22, which is ~3x from current level.
Short interest of ca. 17% will most likely be a fuel once the catalyst events materialize.